AMPK upregulates KCa2.3 channels and ameliorates endothelial dysfunction in diet-induced obese mice
- Biochem Pharmacol. 2021 Jan;183:114337. doi: 10.1016/j.bcp.2020.114337.
- 1. Department of Physiology and Pathophysiology, Cardiovascular Research Centre, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, Xi'an 710061, Shaanxi, China.
- 2. Division of Cardiology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla CA 92093-0613, CA, United States.
- 3. Division of Cardiology, Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla CA 92093-0613, CA, United States. Electronic address: [email protected].
- 4. Department of Physiology and Pathophysiology, Cardiovascular Research Centre, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, Xi'an 710061, Shaanxi, China; Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, Xi'an 710061, Shaanxi, China. Electronic address: [email protected].
The opening of endothelial small-conductance calcium-activated potassium channels (KCA2.3) is essential for endothelium-dependent hyperpolarization (EDH), which predominantly occurs in small resistance arteries. Adenosine monophosphate-activated protein kinase (AMPK), an important metabolic regulator, has been implicated in regulating endothelial nitric oxide synthase activity. However, it was unclear whether AMPK regulated endothelial KCA2.3-mediated EDH-type vasodilation. Using bioinformatics analysis and myograph system, we investigated the regulation by AMPK of KCA2.3 in human umbilical vein endothelial cells (HUVECs) or mouse second-order mesenteric resistance arteries. In HUVECs, AMPK activation either by activators (AICAR, A769662 and MK-8722) or expression of the constitutively active form of AMPK significantly upregulated KCA2.3 expression. Such effects were abolished by AMPK Inhibitor (compound C) or AMPK α1-/α2-siRNA, extracellular-signal-regulated-kinase 5 (ERK5) inhibitor (ERK5-IN-1), and specific siRNA to myocyte-enhancer factor 2 (MEF2) or krüppel-like factor 2/4 (KLF2/4). KCA2.3 expression was significantly reduced in mesenteric resistance arteries in AMPKα2 knockout mice when compared with littermate control mice. Furthermore, in high-fat diet fed mice, 2-week treatment with AICAR restored endothelial KCA2.3 expression in mesenteric resistance arteries with improved endothelial dysfunction. Our results demonstrate that activation of AMPK upregulates KCA2.3 channel expression through the ERK5-MEF2-KLF2/4 signaling pathway in vascular endothelium, which contributes to benefits through KCA2.3-mediated EDH-type vasodilation in mesenteric resistance arteries.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: AMPKResearch Areas: Metabolic Disease